Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: A review of the literature

Current HIV Research

Volumn 7, Issue 6, 2009, Pages 589-596

  Cicalini, Stefania ^a   Chinello, Pierangelo ^a   Grilli, Elisabetta ^a   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiretroviral; Human immunodeficiency virus; Outcome; Pulmonary arterial hypertension; Therapy

Indexed keywords

AMBRISENTAN; BOSENTAN; DIDANOSINE; ILOPROST; LAMIVUDINE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; STAVUDINE; UNIPROST; ZIDOVUDINE;

COMORBIDITY; CONTINUOUS INFUSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOME ASSESSMENT; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SURVIVAL RATE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; PREVALENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73949102022     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209789973583     Document Type: Review

References (78)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425-36.
2. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997; 155: 990-5.
3. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30.
5. Pellicelli AM, Palmieri F, D'Ambrosio C, et al. Role of human immunodeficiency virus in primary pulmonary hypertension - case reports. Angiology 1998; 49: 1005-11.
6. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998; 73: 37-45.
7. Weiss JR, Pietra GG, Scharf SM. Primary pulmonary hypertension and the human immunodeficiency virus. Report of two cases and a review of the literature. Arch Intern Med 1995; 155: 2350-4.
8. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-9.
9. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987; 18: 1293-6.
10. Schulman S, Johnsson H, Blomqvist S. Pulmonary hypertension in hemophilia. Ann Intern Med 1988; 109: 759-60.
11. Goldsmith GH Jr, Baily RG, Brettler DB, et al. Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med 1988; 108: 797-9.
12. Bray GL, Martin GR, Chandra R. Idiopathic pulmonary hypertension, hemophilia A, and infection with human immunodeficiency virus (HIV). Ann Intern Med 1989; 111: 689-90.
13. Himelman RB, Dohrmann M, Goodman P, et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989; 64: 1396-9.
14. Legoux B, Piette AM, Bouchet PF, et al. Pulmonary hypertension and HIV infection. Am J Med 1990; 89: 122.
15. Coplan NL, Shimony RY, Ioachim HL, et al. Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med 1990; 89: 96-9.
16. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100: 1268-71.
17. Saadjian A, Gueunoun M, Philip-Joët F, et al. Pulmonary hypertension secondary to talc microemboli in a HIV seropositive heroin-addict woman. Arch Mal Coeur Vaiss 1991; 84: 1369-73.
18. Aarons EJ, Nye FJ. Primary pulmonary hypertension and HIV infection. AIDS 1991; 5: 1276-7.
19. Hays MD, Wiles HB, Gillette PC. Congenital acquired immunodeficiency syndrome presenting as cor pulmonale in a 10-year-old girl. Am Heart J 1991; 121: 929-31.
20. Maliakkal R, Friedman SA, Sridhar S. Progressive pulmonary thromboembolism in association with HIV disease. N Y State J Med 1992; 92: 403-4.
21. Polos PG, Wolfe D, Harley RA, Strange C, Sahn SA. Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest 1992; 101: 474-8.
22. Jacques C, Richmond G, Tierney L, Curtis JL, McKerrow J, Warnock ML Primary pulmonary hypertension and human immunodeficiency virus infection in a non-hemophiliac man. Hum Pathol 1992; 23: 191-4.
23. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145: 1196-200.
24. Piette AM, Legoux B, Gepner P, Chapman A. "Primary" pulmonary arterial hypertension associated with HIV infection. Two cases. Presse Med 1992; 21: 616-8.
25. Gouello JP, Chennebault JM, Loison J, Causeret H, Pezard P, Achard J. Primary pulmonary arterial hypertension associated with acquired immunodeficiency virus infection. Presse Med 1992; 21: 632-3.
26. Rhodes J, Schiller MS, Montoya CH, Fikrig S. Severe pulmonary hypertension without significant pulmonary parenchymal disease in a pediatric patient with acquired immunodeficiency syndrome. Clin Pediatr 1992; 3: 629-31.
27. Reiser P, Opravil M, Pfaltz M, Speich R, Schneider J. Primary pulmonary hypertension and mesangioproliferative glomerulonephritis in HIV infection. Dtsch Med Wochenschr 1992; 117: 815-8.
28. Duchesne N, Gagnon JA, Fouquette B, et al. Primary pulmonary hypertension associated with HIV infection. Can Assoc Radiol J 1993; 44: 39-41.
29. Diaz PT, Clanton TL. Marked pulmonary function abnormalities in a case of HIV-associated pulmonary hypertension. Chest 1993; 104: 313-5.
30. Martos A, Carratala J, Cabellos C, Rodriguez P. AIDS and primary pulmonary hypertension. Am Heart J 1993; 125: 1819.
31. Arunabh, Edasery B. Human immunodeficiency virus and primary pulmonary hypertension. West J Med 1993; 159: 708-9.
32. De Chadarévian JP, Lischner HW, Karmazin N, Pawel BR, Schultz TE. Pulmonary hypertension and HIV infection: new observations and review of the syndrome. Mod Pathol 1994; 7: 685-9.
33. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722-7.
34. Heron E, Laaban JP, Capron F, Quieffin J, Brechot JM, Rochemaure J. Thrombotic primary pulmonary hypertension in an HIV+ patient. Eur Heart J 1994; 15: 394-6.
35. Mani S, Smith GJ. HIV and pulmonary hypertension: a review. South Med J 1994; 87: 357-62.
36. Ruchelli ED, Nojadera G, Rutstein RM, Rudy B. Pulmonary venoocclusive disease. Another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med 1994; 118: 664-6.
37. Sala-Blanch X, Fábregas N, Martínez JM, Plaza A. Primary pulmonary hypertension in an HIV-positive pregnant woman. Med Clin 1994; 102: 117-8.
38. Zraik N, Herry I, Setbon O, Cadranel J. Primary pulmonary hypertension in a HIV positive patient. Rev Pneumol Clin 1994; 50: 68-70.
39. Escamilla R, Hermant C, Berjaud J, Mazerolles C, Daussy X. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995; 8: 1982-4.
40. Speciale A, Ramundi M, Fabiani F, Fiorucci F, Schmid G. Primary pulmonary hypertension in a HIV+ patient. Monaldi Arch Chest Dis 1995; 50: 451-2.
41. Morse JH, Barst RJ, Fotino M, Zhang Y, Flaster E, Fritzler MJ. Primary pulmonary hypertension: immunogenetic response to high-mobility group (HMG) proteins and histone. Clin Exp Immunol 1996; 106: 389-95.
42. Arranz Caso A, Herrera Serrano L, Cuadrado Gomez LM, Gonzales Estecha A. Primary pulmonary hypertension in a female patient with HIV infection. Rev Clin Esp 1996; 196: 61-2.
43. Monsuez JJ, Auperin I, Vittecoq D, Heshmati F. Pulmonary hypertension associated with thrombotic thrombocytopaenic purpura in AIDS patients. Eur Heart J 1997; 18: 1036-7.
44. Muthiah M, Mishriki YY. Respiratory distress in a former drug abuser. Hosp Pract 1997; 32: 141-4.
45. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28: 434-42.
46. Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension. Ann Intern Med 1997; 127: 1043.
47. Pétureau F, Escamilla R, Hermant C, Mourlanette P, Berjaud J, Krempf M. Pulmonary artery hypertension in HIV seropositive drug addicts. Apropos of 10 cases. Rev Mal Respir 1998; 15: 97-102.
48. Conraads VM, Colebunders RL, Boshoff C, et al. Primary pulmonary hypertension in a patient with HIV infection. Acta Cardiol 1998; 53: 367-9.
49. Fiorencis R, Zonzin P, Carraro M, et al. Pulmonary hypertension associated with human immunodeficiency virus infection. Report of two cases and review of the literature. G Ital Cardiol 1998; 28: 1404-8.
50. Lambiotte F, Chagnon JL, Fontier C, Vermersch A, Socolovsky C. Primary pulmonary hypertension in an HIV-seropositive patient. Presse Med 1999; 28: 582.
51. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118: 1133-41.
52. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846-50.
53. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15: 1747-8.
54. Speich R, Jenni R, Opravil M, Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001; 131: 663-5.
55. Cea-Calvo L, Escribano Subías P, Tello de Menesses R, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol 2003; 56: 421-5.
56. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002; 16: 1568-9.
57. Recusani F, Di Matteo A, Gambarin F, D'Armini A, Klersy C, Campana C. Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension: prospective study of 10 patients. AIDS 2003; 17: S88-95.
58. Ghofrani HA, Rose F, Schermuly RT. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-64.
59. Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A. Longtime survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003; 17: 1714-5.
60. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167: 1433-9.
61. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 1212-7.
62. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38: 1178-85.
63. Zinkernagel AS, von Overbeck J, Opravil M, Jenni R, Speich R, Mueller NJ. Long-term survival and interruption of HAART in HIV-related pulmonary hypertension. Eur J Clin Microbiol Infect Dis 2005; 24: 153-5.
64. Montani D, Achouh L, Marcelin AG, et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J 2005; 26: 969-72.
65. Wong AR, Rasool AH, Abidin NZ, Noor AR, Quah BS. Sildenafil as treatment for Human Immunodeficiency Virus-related pulmonary hypertension in a child. J Paediatr Child Health 2006; 42: 147-8.
66. Petrosillo N, Chinello P, Cicalini S. Pulmonary hypertension in individuals with HIV infection. AIDS 2006; 20: 2128-9.
67. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177: 108-13.
68. Aschmann YZ, Kummer O, Linka A, et al. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors. Ther Drug Monit 2008; 30: 130-4.
69. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008; 22: S35-S40.
70. Reinsch N, Buhr C, Krings P, et al. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med 2008; 9: 550-6.
71. Hsue PY, Deeks SG, Farah HH, et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008; 22: 825-33.
72. Cicalini S, Chinello P, Cicini MP, Petrosillo N. Pulmonary arterial hypertension and HIV infection. AIDS 2008; 22: 2219-20.
73. Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Resp J 2009; 33: 92-8.
74. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-78.
75. Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946: 82-94.
76. Limsukon A, Saeed AI, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J Med 2006; 73: 1037-44.
77. Petrosillo N, Viale P, Nicastri E, et al. Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. Clin Infect Dis 2002; 34: 677-85.
78. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.